Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.

Journal of drugs in dermatology : JDD

Volumn 4, Issue 5, 2005, Pages 544-555

  Weinberg, Jeffrey M ^a   Bottino, Clement J ^a   Lindholm, James ^a   Buchholz, Robin ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; EFALIZUMAB; HYBRID PROTEIN; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

BIOLOGICAL THERAPY; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; IMMUNOLOGY; PSORIASIS; REVIEW; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; BIOLOGICAL THERAPY; HUMANS; IMMUNOGLOBULIN G; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 27144501683     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)